JPH0678246B2 - 診断用組成物 - Google Patents

診断用組成物

Info

Publication number: JPH0678246B2
Authority: JP; Japan
Prior art keywords: paramagnetic metal; polymeric; particles; water; composition according
Prior art date: 1984-11-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP60244240A

Other languages

English (en)

Japanese (ja)

Other versions

JPS61155338A (ja

Inventor

トロンド・ヤコブセン

ヨー・クラーヴエネス

ベルント・ヤーベス・リンドベルイ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Nyegaard and Co AS

Original Assignee

Nyegaard and Co AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-11-01

Filing date

1985-11-01

Publication date

1994-10-05

1984-11-01 Priority claimed from SE8405501A external-priority patent/SE465909B/sv

1984-11-01 Priority claimed from SE8405500A external-priority patent/SE465908B/sv

1985-11-01 Application filed by Nyegaard and Co AS filed Critical Nyegaard and Co AS

1986-07-15 Publication of JPS61155338A publication Critical patent/JPS61155338A/ja

1994-10-05 Publication of JPH0678246B2 publication Critical patent/JPH0678246B2/ja

2009-10-05 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims description 66
239000002245 particle Substances 0.000 claims description 135
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 90
229910052751 metal Inorganic materials 0.000 claims description 84
239000002184 metal Substances 0.000 claims description 84
230000005298 paramagnetic effect Effects 0.000 claims description 65
239000000126 substance Substances 0.000 claims description 61
239000000463 material Substances 0.000 claims description 41
229920000642 polymer Polymers 0.000 claims description 26
229920002472 Starch Polymers 0.000 claims description 25
239000008107 starch Substances 0.000 claims description 25
235000019698 starch Nutrition 0.000 claims description 24
150000001720 carbohydrates Chemical class 0.000 claims description 19
235000014633 carbohydrates Nutrition 0.000 claims description 19
238000000034 method Methods 0.000 claims description 18
229910052757 nitrogen Inorganic materials 0.000 claims description 15
230000002285 radioactive effect Effects 0.000 claims description 15
150000005846 sugar alcohols Chemical class 0.000 claims description 15
239000002253 acid Substances 0.000 claims description 13
125000004429 atom Chemical group 0.000 claims description 13
150000004697 chelate complex Chemical class 0.000 claims description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
150000004676 glycans Chemical class 0.000 claims description 11
125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
229920001282 polysaccharide Polymers 0.000 claims description 11
239000005017 polysaccharide Substances 0.000 claims description 11
229910052717 sulfur Inorganic materials 0.000 claims description 10
239000013522 chelant Substances 0.000 claims description 8
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 7
239000012736 aqueous medium Substances 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
125000004434 sulfur atom Chemical group 0.000 claims description 7
102000004139 alpha-Amylases Human genes 0.000 claims description 6
108090000637 alpha-Amylases Proteins 0.000 claims description 6
229940024171 alpha-amylase Drugs 0.000 claims description 6
239000007900 aqueous suspension Substances 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 5
239000002198 insoluble material Substances 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
241001465754 Metazoa Species 0.000 claims description 4
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
229920002307 Dextran Polymers 0.000 claims description 3
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
229910052688 Gadolinium Inorganic materials 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
239000011651 chromium Substances 0.000 claims description 3
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 3
239000002195 soluble material Substances 0.000 claims description 3
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
229910052692 Dysprosium Inorganic materials 0.000 claims description 2
229910052691 Erbium Inorganic materials 0.000 claims description 2
229910052693 Europium Inorganic materials 0.000 claims description 2
229910052689 Holmium Inorganic materials 0.000 claims description 2
102000004157 Hydrolases Human genes 0.000 claims description 2
108090000604 Hydrolases Proteins 0.000 claims description 2
229910052804 chromium Inorganic materials 0.000 claims description 2
229910052802 copper Inorganic materials 0.000 claims description 2
239000010949 copper Substances 0.000 claims description 2
KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims description 2
UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims description 2
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 2
KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 claims description 2
229910052742 iron Inorganic materials 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
229910052759 nickel Inorganic materials 0.000 claims description 2
239000002562 thickening agent Substances 0.000 claims description 2
125000003368 amide group Chemical group 0.000 claims 1
125000004185 ester group Chemical group 0.000 claims 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
230000003204 osmotic effect Effects 0.000 claims 1
239000000725 suspension Substances 0.000 description 77
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 66
239000012153 distilled water Substances 0.000 description 56
239000000243 solution Substances 0.000 description 39
239000006228 supernatant Substances 0.000 description 21
239000011324 bead Substances 0.000 description 20
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
229960003330 pentetic acid Drugs 0.000 description 15
238000005481 NMR spectroscopy Methods 0.000 description 14
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
-1 dihydroxypropyl Chemical group 0.000 description 13
125000004432 carbon atom Chemical group C* 0.000 description 10
125000004430 oxygen atom Chemical group O* 0.000 description 10
150000001875 compounds Chemical class 0.000 description 8
238000004132 cross linking Methods 0.000 description 7
238000003756 stirring Methods 0.000 description 7
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000007864 aqueous solution Substances 0.000 description 6
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
210000001035 gastrointestinal tract Anatomy 0.000 description 6
239000002609 medium Substances 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
239000003431 cross linking reagent Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
239000007863 gel particle Substances 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
RAEOEMDZDMCHJA-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O RAEOEMDZDMCHJA-UHFFFAOYSA-N 0.000 description 4
239000002585 base Substances 0.000 description 4
238000003384 imaging method Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
239000012876 carrier material Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000007822 coupling agent Substances 0.000 description 3
238000002405 diagnostic procedure Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
125000000468 ketone group Chemical group 0.000 description 3
239000011572 manganese Substances 0.000 description 3
229910021645 metal ion Inorganic materials 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
230000000379 polymerizing effect Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
239000011593 sulfur Substances 0.000 description 3
210000004291 uterus Anatomy 0.000 description 3
NKIJBSVPDYIEAT-UHFFFAOYSA-N 1,4,7,10-tetrazacyclododec-10-ene Chemical compound C1CNCCN=CCNCCN1 NKIJBSVPDYIEAT-UHFFFAOYSA-N 0.000 description 2
VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
229920001917 Ficoll Polymers 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
229930194542 Keto Natural products 0.000 description 2
229910002651 NO3 Inorganic materials 0.000 description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
125000002648 azanetriyl group Chemical group *N(*)* 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001718 carbodiimides Chemical class 0.000 description 2
150000007942 carboxylates Chemical class 0.000 description 2
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
239000000969 carrier Substances 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
125000001033 ether group Chemical group 0.000 description 2
WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
230000005291 magnetic effect Effects 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
230000001376 precipitating effect Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000007858 starting material Substances 0.000 description 2
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
230000008961 swelling Effects 0.000 description 2
229920001059 synthetic polymer Polymers 0.000 description 2
238000012360 testing method Methods 0.000 description 2
KBMBVTRWEAAZEY-UHFFFAOYSA-N trisulfane Chemical compound SSS KBMBVTRWEAAZEY-UHFFFAOYSA-N 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
210000003932 urinary bladder Anatomy 0.000 description 2
ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
RAZLJUXJEOEYAM-UHFFFAOYSA-N 2-[bis[2-(2,6-dioxomorpholin-4-yl)ethyl]azaniumyl]acetate Chemical compound C1C(=O)OC(=O)CN1CCN(CC(=O)O)CCN1CC(=O)OC(=O)C1 RAZLJUXJEOEYAM-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
229920000945 Amylopectin Polymers 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical compound NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
229920002670 Fructan Polymers 0.000 description 1
229920001503 Glucan Polymers 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
101001132499 Homo sapiens RPA-related protein RADX Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229920001202 Inulin Polymers 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
229920001218 Pullulan Polymers 0.000 description 1
239000004373 Pullulan Substances 0.000 description 1
102100033967 RPA-related protein RADX Human genes 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
WJKJXKRHMUXQSL-UHFFFAOYSA-N benzyl glycinate 4-methylbenzenesulfonate salt Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.NCC(=O)OCC1=CC=CC=C1 WJKJXKRHMUXQSL-UHFFFAOYSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000012662 bulk polymerization Methods 0.000 description 1
150000004651 carbonic acid esters Chemical group 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
229940106681 chloroacetic acid Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000000151 deposition Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000012674 dispersion polymerization Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
150000002019 disulfides Chemical class 0.000 description 1
AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical group C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
125000001183 hydrocarbyl group Chemical group 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
229940029339 inulin Drugs 0.000 description 1
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229910001463 metal phosphate Inorganic materials 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
239000000178 monomer Substances 0.000 description 1
LSHROXHEILXKHM-UHFFFAOYSA-N n'-[2-[2-[2-(2-aminoethylamino)ethylamino]ethylamino]ethyl]ethane-1,2-diamine Chemical compound NCCNCCNCCNCCNCCN LSHROXHEILXKHM-UHFFFAOYSA-N 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
125000001477 organic nitrogen group Chemical group 0.000 description 1
150000002924 oxiranes Chemical class 0.000 description 1
125000000466 oxiranyl group Chemical group 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
235000019423 pullulan Nutrition 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
238000007873 sieving Methods 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000000185 sucrose group Chemical group 0.000 description 1
230000008719 thickening Effects 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
229920003176 water-insoluble polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
- A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/806—Electrical property or magnetic property
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Radiology & Medical Imaging (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Nanotechnology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP60244240A 1984-11-01 1985-11-01 診断用組成物 Expired - Lifetime JPH0678246B2 (ja)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
SE8405501-1		1984-11-01
SE8405500-3		1984-11-01
SE8405501A SE465909B (sv)	1984-11-01	1984-11-01	Partikelformat diagnosticeringsmedel innehaallande en paramagnetisk metall
SE8405500A SE465908B (sv)	1984-11-01	1984-11-01	Diagnosticeringspartiklar innehaallande en paramagnetisk metall

Publications (2)

Publication Number	Publication Date
JPS61155338A JPS61155338A (ja)	1986-07-15
JPH0678246B2 true JPH0678246B2 (ja)	1994-10-05

Family

ID=26658808

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP60244240A Expired - Lifetime JPH0678246B2 (ja)	1984-11-01	1985-11-01	診断用組成物

Country Status (6)

Country	Link
US (1)	US4985233A (da)
EP (1)	EP0184899B1 (da)
JP (1)	JPH0678246B2 (da)
DE (1)	DE3577185D1 (da)
DK (1)	DK164486C (da)
NO (1)	NO169525C (da)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0330801A1 (en) *	1983-02-08	1989-09-06	Schering Aktiengesellschaft	Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
US4735796A (en) *	1983-12-08	1988-04-05	Gordon Robert T	Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
US6203777B1 (en) *	1983-12-21	2001-03-20	Nycomed Imaging As	Method of contrast enhanced magnetic resonance imaging using carbohydrate particles
SE463651B (sv) *	1983-12-21	1991-01-07	Nycomed As	Diagnostikum och kontrastmedel
AU6621586A (en) *	1985-11-18	1987-06-02	University Of Texas System, The	Polychelating agents for image and spectral enhancement (and spectral shift)
US5336762A (en) *	1985-11-18	1994-08-09	Access Pharmaceuticals, Inc.	Polychelating agents for image and spectral enhancement (and spectral shift)
US5284646A (en) *	1986-07-03	1994-02-08	Advanced Magnetics Inc.	Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents
US5352432A (en) *	1986-07-03	1994-10-04	Advanced Magnetics, Inc.	Hepatocyte specific composition and their use as diagnostic imaging agents
US5342607A (en) *	1986-07-03	1994-08-30	Advanced Magnetics, Inc.	Receptor mediated endocytosis type magnetic resonance imaging contrast agents
US4770183A (en) *	1986-07-03	1988-09-13	Advanced Magnetics Incorporated	Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US4951675A (en) *	1986-07-03	1990-08-28	Advanced Magnetics, Incorporated	Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging
US5679323A (en) *	1986-07-03	1997-10-21	Advanced Magnetics, Inc.	Hepatocyte-specific receptor-mediated endocytosis-type compositions
US5219554A (en)	1986-07-03	1993-06-15	Advanced Magnetics, Inc.	Hydrated biodegradable superparamagnetic metal oxides
FR2612400A1 (fr) *	1987-03-16	1988-09-23	Centre Nat Rech Scient	Microcapsules contenant un marqueur radioactif et/ou paramagnetique sous forme de chelate, et leur utilisation dans le domaine de l'imagerie medicale
DE3709851A1 (de) *	1987-03-24	1988-10-06	Silica Gel Gmbh Adsorptions Te	Nmr-diagnostische fluessigkeitszusammensetzungen
DE3710730A1 (de) *	1987-03-31	1988-10-20	Schering Ag	Substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US5049667A (en) *	1987-04-14	1991-09-17	Guerbet S.A.	Nitrogen-containing cyclic ligands
US5154179A (en) *	1987-07-02	1992-10-13	Medical Magnetics, Inc.	Device construction and method facilitating magnetic resonance imaging of foreign objects in a body
DE3724188C2 (de) *	1987-07-17	1995-05-18	Heinz Dr Gries	Metallhaltige Oligosaccharid-Polysulfate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
US6013531A (en) *	1987-10-26	2000-01-11	Dade International Inc.	Method to use fluorescent magnetic polymer particles as markers in an immunoassay
GB8801646D0 (en) *	1988-01-26	1988-02-24	Nycomed As	Chemical compounds
GB8813144D0 (en) *	1988-06-03	1988-07-06	Nycomed As	Compositions
JPH04501218A (ja)	1988-08-04	1992-03-05	アドヴァンスド　マグネティックス　インコーポレーティッド	受容体媒介エンドサイト―シス型ｍｒｉ造影剤
US5213788A (en) *	1988-09-29	1993-05-25	Ranney David F	Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
US5314681A (en) *	1988-12-23	1994-05-24	Nycomed Innovation Ab	Composition of positive and negative contrast agents for electron spin resonance enhanced magnetic resonance imaging
US5393525A (en) *	1989-07-21	1995-02-28	Nycomed Imaging As	Contrast medium comprising superparamagnetic or ferromagnetic particles capable of increasing viscosity after administration
GB8916782D0 (en) *	1989-07-21	1989-09-06	Nycomed As	Compositions
GB8916781D0 (en) *	1989-07-21	1989-09-06	Nycomed As	Compositions
GB8916780D0 (en) *	1989-07-21	1989-09-06	Nycomed As	Compositions
US5358702A (en) *	1990-04-10	1994-10-25	Unger Evan C	Methoxylated gel particle contrast media for improved diagnostic imaging
US5368840A (en) *	1990-04-10	1994-11-29	Imarx Pharmaceutical Corp.	Natural polymers as contrast media for magnetic resonance imaging
ATE153860T1 (de) *	1990-04-10	1997-06-15	Imarx Pharmaceutical Corp	Polymere und ihre verwendung als kontrastmittel bei der bilderzeugung mit magnetischer resonanz
US5215680A (en) *	1990-07-10	1993-06-01	Cavitation-Control Technology, Inc.	Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
US5268165A (en) *	1990-10-16	1993-12-07	Biomedical Frontiers, Inc.	Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging
US5236693A (en) *	1990-11-14	1993-08-17	Brigham And Women's Hospital	Medical ultrasound contrast agent and method of using same
US5370901A (en) *	1991-02-15	1994-12-06	Bracco International B.V.	Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
GB9106686D0 (en) *	1991-03-28	1991-05-15	Hafslund Nycomed As	Improvements in or relating to contrast agents
US5310539A (en) *	1991-04-15	1994-05-10	Board Of Regents, The University Of Texas System	Melanin-based agents for image enhancement
DE4115789A1 (de) *	1991-05-10	1992-11-12	Schering Ag	Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
WO1992021382A1 (en) *	1991-06-03	1992-12-10	Holmes, Michael, John	Improvements in or relating to contrast agents
JP2939336B2 (ja) *	1991-06-11	1999-08-25	名糖産業株式会社	水溶性カルボキシ多糖−磁性酸化鉄酸化複合体
DE69203080T2 (de) *	1991-06-17	1996-02-01	Dade International Inc., Deerfield, Ill.	Verfahren zur Herstellung magnetisch empfindlicherPolymerpartikel und ihre Anwendung.
US5250284A (en) *	1991-10-15	1993-10-05	Arnon Krongrad	Method for increasing nuclear magnetic resonance signals in living biological tissue using zinc
JPH07501331A (ja) *	1991-11-19	1995-02-09	イマアーレクス・フアーマシユーチカル・コーポレーシヨン	改良された診断用の造影のためのゲル粒子造影剤
GB9200388D0 (en) *	1992-01-09	1992-02-26	Nycomed As	Improvements in or relating to contrast agents
JP2911674B2 (ja) *	1992-02-20	1999-06-23	明治乳業株式会社	消化管造影用組成物
EP0565930A1 (en) *	1992-03-27	1993-10-20	Nihon Medi-Physics Co., Ltd.	Tetraazacyclododecane tetraacetic acid derivatives and the use thereof as diagnostic agents
DK0580878T3 (da) *	1992-06-01	1996-02-12	Basf Ag	Anvendelse af dispersioner af magneto-ioniske partikler som MRI-kontrastmedier
WO1994002068A1 (en) *	1992-07-21	1994-02-03	The General Hospital Corporation	System of drug delivery to the lymphatic tissues
WO1994009056A1 (en) *	1992-10-14	1994-04-28	Sterling Winthrop Inc.	Chelating polymers
US5817292A (en) *	1992-10-14	1998-10-06	Nycomed Imaging As	MR imaging compositions and methods
JPH08502300A (ja) *	1992-10-14	1996-03-12	スターリングウィンスロップアイエヌシー．	治療および診断像形成組成物および方法
US5401492A (en) *	1992-12-17	1995-03-28	Sterling Winthrop, Inc.	Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
CA2154667A1 (en) *	1993-02-02	1994-08-18	Linda M. Gustavson	Directed biodistribution of small molecules
US5532006A (en) *	1993-04-23	1996-07-02	The Board Of Trustees Of The University Of Illinois	Magnetic gels which change volume in response to voltage changes for MRI
US6122540A (en) *	1994-06-08	2000-09-19	The Regents Of The University Of California	Noninvasive measurement of renal hemodynamic functions using magnetic resonance imaging
DE4428851C2 (de) *	1994-08-04	2000-05-04	Diagnostikforschung Inst	Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
ZA958789B (en) *	1994-10-21	1996-05-29	Nihon Mediphysics Co Ltd	Diagnostic imaging agent
DK81095A (da) *	1995-07-11	1997-01-12	Henrik S Thomsen	Peroralt MR-kontraststof til lever og øvre tarmkanal
FR2749082B1 (fr) *	1996-05-24	1998-06-26	Bio Merieux	Particules superparamagnetiques et monodispersees
NL1003776C2 (nl) *	1996-08-09	1998-02-20	Cooperatie Cosun U A	Milieuvriendelijke complexanten voor zware metalen
AU7104598A (en)	1997-04-09	1998-10-30	Philipp Lang	New technique to monitor drug delivery noninvasively (in vivo)
JP4927302B2 (ja) *	2000-09-21	2012-05-09	グラステクインコーポレイテッド	ガラス板用関節成形型
US20030100830A1 (en) *	2001-11-27	2003-05-29	Sheng-Ping Zhong	Implantable or insertable medical devices visible under magnetic resonance imaging
US20040143180A1 (en) *	2001-11-27	2004-07-22	Sheng-Ping Zhong	Medical devices visible under magnetic resonance imaging
WO2004004786A1 (en) *	2002-07-02	2004-01-15	Universitair Medisch Centrum Utrecht	Scanning suspension comprising a particle with a diameter of at least 1 micrometer
ATE400302T1 (de) *	2002-07-22	2008-07-15	Bracco Imaging Spa	Zellmarkierungsverfahren mit paramagnetischen komplexen für mrt-anwendungen
US8620406B2 (en) *	2004-01-23	2013-12-31	Boston Scientific Scimed, Inc.	Medical devices visible by magnetic resonance imaging
US7761138B2 (en)	2004-03-12	2010-07-20	Boston Scientific Scimed, Inc.	MRI and X-ray visualization
US7483732B2 (en) *	2004-04-15	2009-01-27	Boston Scientific Scimed, Inc.	Magnetic resonance imaging of a medical device and proximate body tissue
EP1793860B1 (en) *	2004-07-15	2009-08-05	GynaecologIQ B.V.	Composition and method for medical imaging of body cavities
US7778684B2 (en) *	2005-08-08	2010-08-17	Boston Scientific Scimed, Inc.	MRI resonator system with stent implant
US20070239256A1 (en) *	2006-03-22	2007-10-11	Jan Weber	Medical devices having electrical circuits with multilayer regions
US8759109B2 (en)	2008-03-11	2014-06-24	Urobiologics Llc	Use of female mammal's urine for determination of fetal gender related characteristics
US10996218B2 (en)	2008-03-11	2021-05-04	Ournextbaby Llc	Methods for chemotaxis / redox driven separation of X and Y chromosome bearing sperm and their insemination in gender specific menstrual cycles
NL2003660C2 (en)	2009-10-16	2011-04-19	Giskit B V	Composition and method for medical imaging of body cavities.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2862920A (en) *	1956-06-07	1958-12-02	Ohio Commw Eng Co	Ferrous carboxymethyl dextran
GB1175834A (en) *	1966-04-07	1969-12-23	Atomic Energy Authority Uk	Improvements in or relating to the Chemical Production of Metal-Containing Materials as Particles and other Configurations
US3563978A (en) *	1968-05-15	1971-02-16	Irving L Ochs	Polyvalent metal complexes of natural polymers
US3928581A (en) *	1972-09-13	1975-12-23	Astra Laekemedel Ab	Certain polymer-iron complexes for treatment of iron deficiency
SE431214B (sv) *	1977-06-02	1984-01-23	Klaus H Mosbach	Sett att framstella magnetiska polymerpartiklar som berare av en foretredesvis biologiskt aktiv substans
SE409694B (sv)	1978-01-02	1979-09-03	Odlund Bjorn Alf Ingemar	Lastningsmaskin
US4370476A (en) *	1979-07-17	1983-01-25	Usher Thomas C	Dextran polycarboxylic acids, ferric hydroxide complexes
DE3129906C3 (de) *	1981-07-24	1996-12-19	Schering Ag	Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik
US4647447A (en) *	1981-07-24	1987-03-03	Schering Aktiengesellschaft	Diagnostic media
US4452773A (en) *	1982-04-05	1984-06-05	Canadian Patents And Development Limited	Magnetic iron-dextran microspheres
HU186077B (en) *	1982-06-16	1985-05-28	Afit Iv Autojavito Vallalat	Device for blocking the hand brake lever
US4731239A (en) *	1983-01-10	1988-03-15	Gordon Robert T	Method for enhancing NMR imaging; and diagnostic use
CA1244082A (en) *	1983-01-10	1988-11-01	Robert T. Gordon	Method for enhancing nmr imaging; and diagnostic use
NL194579C (nl) *	1983-01-21	2002-08-05	Schering Ag	Diagnostisch middel.
US4423158A (en) *	1983-01-27	1983-12-27	Gelinnovation Handelsaktiebolag	Ion adsorbent for metals having a coordination number greater than two
DK148251C (da)	1983-02-18	1985-10-14	Dansk Gartneri Tek As	Lukkemekanisme til under et tag paa raekke ophaengte gardinparter
CA1242643A (en) *	1983-08-12	1988-10-04	Eric T. Fossel	Nmr imaging utilizing chemical shift reagents
FR2550449B1 (fr) *	1983-08-12	1986-01-31	Commissariat Energie Atomique	Agents de relaxation specifiques d'organes ou de pathologies, utilisables pour modifier les contrastes en imagerie medicale par resonance magnetique nucleaire
CA1243602A (en) *	1983-08-25	1988-10-25	Hong-Ning Yeung	Methods for enhancing the contrast in nmr imaging
US4615879A (en) *	1983-11-14	1986-10-07	Vanderbilt University	Particulate NMR contrast agents for gastrointestinal application
SE463651B (sv) *	1983-12-21	1991-01-07	Nycomed As	Diagnostikum och kontrastmedel
US4728575A (en) *	1984-04-27	1988-03-01	Vestar, Inc.	Contrast agents for NMR imaging
GB8413849D0 (en) *	1984-05-31	1984-07-04	Amersham Int Plc	Nmr contrast agents
JPS6162785A (ja)	1984-09-04	1986-03-31	日本プライブリコ株式会社	耐摩耗・耐火材ライニング用アンカ−
US4675173A (en) *	1985-05-08	1987-06-23	Molecular Biosystems, Inc.	Method of magnetic resonance imaging of the liver and spleen
US4822594A (en) *	1987-01-27	1989-04-18	Gibby Wendell A	Contrast enhancing agents for magnetic resonance images

1985
- 1985-10-25 DE DE8585307738T patent/DE3577185D1/de not_active Expired - Lifetime
- 1985-10-25 EP EP85307738A patent/EP0184899B1/en not_active Expired - Lifetime
- 1985-10-31 DK DK500085A patent/DK164486C/da active
- 1985-10-31 NO NO854349A patent/NO169525C/no unknown
- 1985-11-01 JP JP60244240A patent/JPH0678246B2/ja not_active Expired - Lifetime
- 1985-11-01 US US06/793,899 patent/US4985233A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO169525B (no)	1992-03-30
EP0184899B1 (en)	1990-04-18
DK164486C (da)	1992-11-23
NO169525C (no)	1992-07-08
EP0184899A1 (en)	1986-06-18
US4985233A (en)	1991-01-15
JPS61155338A (ja)	1986-07-15
DK500085D0 (da)	1985-10-31
DK164486B (da)	1992-07-06
DE3577185D1 (de)	1990-05-23
NO854349L (no)	1986-05-02
DK500085A (da)	1986-05-02

Publication	Publication Date	Title
EP0184899B1 (en)	1990-04-18	Paramagnetic contrast agents for use in "in vivo" diagnostic methods using nmr, and their preparation
EP0186947B1 (en)	1990-07-11	Paramagnetic contrast agents for use in "in vivo" diagnostic methods using nmr, and their preparation
RU2081881C1 (ru)	1997-06-20	Макромолекулярное парамагнитное соединение, способ получения макромолекулярного парамагнитного соединения, диагностическое контрастное средство, способ получения диагностического контрастного средства
AU624132B2 (en)	1992-06-04	Contrast agents for magnetic resonance imaging
US5653959A (en)	1997-08-05	Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
JP4280304B2 (ja)	2009-06-17	造影剤
US5023072A (en)	1991-06-11	Paramagnetic/superparamagnetic/ferromagnetic sucrose sulfate compositions for magnetic resonance imaging of the gastrointestinal tract
JPH08501097A (ja)	1996-02-06	臨床診断及び治療用部分を含む生体適合性ポリマー
JPH066538B2 (ja)	1994-01-26	コントラスト剤
JP4163381B2 (ja)	2008-10-08	生理学的薬剤の検出のための磁気共鳴造影剤
JP2001523215A (ja)	2001-11-20	ハイブリッド磁気共鳴造影剤
JPH10509424A (ja)	1998-09-14	磁気共鳴イメージングで顕著な効果を示すキレート錯体
AU623901B2 (en)	1992-05-28	Paramagnetic compounds comprising chelating moiety, linker group macro molecule and paramagnetic metal
SE465908B (sv)	1991-11-18	Diagnosticeringspartiklar innehaallande en paramagnetisk metall
SE465909B (sv)	1991-11-18	Partikelformat diagnosticeringsmedel innehaallande en paramagnetisk metall